Rules and Regulations. Notice
415 words·~2 min read·
/register/2020/03/17/2020-05354A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4184-09-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket Nos. FDA-2019-N-3077; FDA-2013-N-0403; FDA-2013-N-0579; FDA-2016-N-2474; FDA-2013-N-0717; FDA-2018-N-3728; FDA-2013-N-0797; FDA-2013-N-0578; FDA-2013-N-0879; FDA-2012-N-0197; FDA-2016-N-3586; FDA-2016-N-4319; and FDA-2013-N-0764] Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration
(FDA)is publishing a list of information collections that have been approved by the Office of Management and Budget
(OMB)under the Paperwork Reduction Act of 1995. FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, *PRAStaff@fda.hhs.gov.* SUPPLEMENTARY INFORMATION: The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at *http://www.reginfo.gov/public/do/PRAMain.* An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Table 1—List of Information Collections Approved By OMB Title of collection OMB Control No. Date approval expires Obtaining Information to Understand Challenges and Opportunities Encountered by Compounding Outsourcing Facilities 0910-0883 1/31/2021 Protection of Human Subjects; Informed Consent; and Institutional Boards 0910-0130 1/31/2023 Biological Products: Reporting and Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Deviations in Manufacturing 0910-0458 1/31/2023 Reporting Associated with Designated New Animal Drugs for Minor Use and Minor Species 0910-0605 1/31/2023 Evaluation of the Food and Drug Administration's General Market Youth Tobacco Prevention Campaign 0910-0753 1/31/2023 Collection of Conflict of Interest Information for Participation in Food and Drug Administration Non-Employee Fellowship and Traineeship Programs 0910-0882 1/31/2023 Human Tissue Intended for Transplantation 0910-0302 2/28/2023 General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling, Revocation and Suspension, Postmarketing Studies Status Reports, and Form FDA 356h 0910-0338 2/28/2023 Procedures for the Safe Processing and Importing of Fish and Fishery Products 0910-0354 2/28/2023 Medical Devices; Shortages Data Collection System 0910-0491 2/28/2023 Focus Groups About Drug Products as Used by the Food and Drug Administration 0910-0677 2/28/2023 Unique Device Identification System 0910-0720 2/28/2023 Animal Feed Regulatory Program Standards 0910-0760 2/28/2023 Dated: March 11, 2020. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2020-05354 Filed 3-16-20; 8:45 am]
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Rules and Regulations
Notice
Cites 1Cited by 0 across 0 sources